Novasys Medical
This article was originally published in The Gray Sheet
Executive Summary
Non-surgical treatment for female stress urinary incontinence gains expanded R&D funding via $13 mil. private placement of preferred stock. Delphi Ventures, Onset Ventures, Alloy Ventures, Affinity Capital Advisors and Rothschild Bioscience Managers participated in the financing. A pilot study of 41 women with SUI in Chile and Mexico has been completed, and clinical results are being analyzed, Sunnyvale, California-based Novasys says. The radiofrequency catheter-based, bladder outlet remodeling device works by increasing bladder outlet resistance